54. R. Rossin, M.S. Robillard, Pretargeted imaging using bioorthogonal chemistry in mice. Curr.
Opin. Chem. Biol. 21, 161–169 (2014)
55. R. Rossin, P. Renart Verkerk, S.M. van den Bosch, R.C.M. Vulders, I. Verel, J. Lub et al., In
vivo chemistry for pretargeted tumor imaging in live mice. Angew. Chem. Int. Ed. Engl. 122
(19), 3447–3450 (2010)
56. B.M. Zeglis, K.K. Sevak, T. Reiner, P. Mohindra, S.D. Carlin, P. Zanzonico et al., A
pretargeted PET imaging strategy based on bioorthogonal Diels–Alder click chemistry.
J. Nucl. Med. 54(8), 1389–1396 (2013)
57. S. Hou, J. Choi, M.A. Garcia, Y. Xing, K.-J. Chen, Y.-M. Chen et al., Pretargeted positron
emission tomography imaging that employs supramolecular nanoparticles with in vivo
bioorthogonal chemistry. ACS Nano 10(1), 1417–1424 (2016)
58. H. Maeda, The enhanced permeability and retention (EPR) effect in tumor vasculature: the
key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41(1), 189–
207 (2001)
59. H. Maeda, H. Nakamura, J. Fang, The EPR effect for macromolecular drug delivery to solid
tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor
imaging in vivo. Adv. Drug Deliv. Rev. 65(1), 71–79 (2013)
60. C. Heneweer, J.P. Holland, V. Divilov, S. Carlin, J.S. Lewis, Magnitude of enhanced
permeability and retention effect in tumors with different phenotypes:
89
Zr-albumin as a
model system. J. Nucl. Med. 52(4), 625–633 (2011)
61. O. Keinänen, E.M. Mäkilä, R. Lindgren, H. Virtanen, H. Liljenbäck, V. Oikonen et al.,
Pretargeted PET imaging of trans-cyclooctene-modified porous silicon nanoparticles. ACS
Omega 2(1), 62–69 (2017)
262
J. C. Knight and B. Cornelissen
Opin. Chem. Biol. 21, 161–169 (2014)
55. R. Rossin, P. Renart Verkerk, S.M. van den Bosch, R.C.M. Vulders, I. Verel, J. Lub et al., In
vivo chemistry for pretargeted tumor imaging in live mice. Angew. Chem. Int. Ed. Engl. 122
(19), 3447–3450 (2010)
56. B.M. Zeglis, K.K. Sevak, T. Reiner, P. Mohindra, S.D. Carlin, P. Zanzonico et al., A
pretargeted PET imaging strategy based on bioorthogonal Diels–Alder click chemistry.
J. Nucl. Med. 54(8), 1389–1396 (2013)
57. S. Hou, J. Choi, M.A. Garcia, Y. Xing, K.-J. Chen, Y.-M. Chen et al., Pretargeted positron
emission tomography imaging that employs supramolecular nanoparticles with in vivo
bioorthogonal chemistry. ACS Nano 10(1), 1417–1424 (2016)
58. H. Maeda, The enhanced permeability and retention (EPR) effect in tumor vasculature: the
key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41(1), 189–
207 (2001)
59. H. Maeda, H. Nakamura, J. Fang, The EPR effect for macromolecular drug delivery to solid
tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor
imaging in vivo. Adv. Drug Deliv. Rev. 65(1), 71–79 (2013)
60. C. Heneweer, J.P. Holland, V. Divilov, S. Carlin, J.S. Lewis, Magnitude of enhanced
permeability and retention effect in tumors with different phenotypes:
89
Zr-albumin as a
model system. J. Nucl. Med. 52(4), 625–633 (2011)
61. O. Keinänen, E.M. Mäkilä, R. Lindgren, H. Virtanen, H. Liljenbäck, V. Oikonen et al.,
Pretargeted PET imaging of trans-cyclooctene-modified porous silicon nanoparticles. ACS
Omega 2(1), 62–69 (2017)
262
J. C. Knight and B. Cornelissen